Anthropic IPO Marketing Expected to Start in Mid-October 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
ING Says Yen Is 20% Undervalued Against Dollar 
China is launching a Moon mission to find water ice. It’s unlike anything NASA has done 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Jefferies Names 6 Top India Stock Picks Across Key Sectors 
Add as a preferred source on Google
JPMorgan has reinstated coverage and price targets on 14 major biotechnology companies, signaling renewed confidence in the biotech sector as firms transform successful drug pipelines into profitable commercial businesses. According to analysts led by Jessica Fye, the industry is approaching a major “inflection point,” driven by improving profitability, expanding product portfolios, and upcoming clinical catalysts.
The investment bank highlighted several biotech companies that have already reached sustained profitability, including Alnylam Pharmaceuticals, BeOne Medicines, and Ascendis Pharma. Meanwhile, Insmed and Ionis Pharmaceuticals are expected to achieve profitability soon, creating opportunities for stronger margins and long-term revenue growth.
JPMorgan also emphasized the growing diversification strategies among biotech firms. Vertex Pharmaceuticals is expanding beyond its core business into renal disease treatments, while BioMarin continues strengthening its rare disease pipeline through acquisitions. Moderna is broadening the use of its mRNA technology into oncology despite ongoing financial concerns surrounding the company.
The report pointed to multiple upcoming clinical trial updates that could boost investor sentiment across the biotechnology market. Analysts expect major cardiovascular outcomes data related to Ionis-partnered therapies and important renal disease readouts from Vertex Pharmaceuticals to act as key catalysts over the next year.
JPMorgan assigned “Overweight” ratings to several biotech stocks, including Vertex Pharmaceuticals, Alnylam, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis, BioMarin, and Mirum Pharmaceuticals. Meanwhile, BioNTech, Incyte, and Halozyme received “Neutral” ratings. Moderna was rated “Underweight” due to concerns over financial risks despite progress in cancer research and mRNA development.
The bank also released updated price targets for December 2026. Vertex received a target of $515, Alnylam $420, BeOne Medicines $415, United Therapeutics $685, and Insmed $180. Moderna’s target was set at $40, while BioNTech received a $100 target.
JPMorgan believes the biotech sector is entering a period of durable expansion as companies scale beyond dependence on single products and continue building diversified, profitable healthcare franchises.
